{
    "root": "7ec5f8ea-6c1f-41c7-929a-7e8acc7ff63a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clozapine",
    "value": "20240906",
    "ingredients": [
        {
            "name": "CLOZAPINE",
            "code": "J60AR2IKIC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3766"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2877"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "PEPPERMINT",
            "code": "V95R5KMY2B",
            "drugbank_id": "https://go.drugbank.com/drugs/DB10984"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00815"
        },
        {
            "name": "XYLITOL",
            "code": "VCQ006KQ1E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17151"
        }
    ],
    "indications": {
        "text": "clozapine orally disintegrating tablets atypical antipsychotic indicated : treatment-resistant schizophrenia . efficacy established active-controlled study . ( 1.1 , 14.1 ) reducing suicidal behavior patients schizophrenia schizoaffective disorder . efficacy established active-controlled study . ( 1.2 , 14.2 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "schizoaffective disorder (DOID:5418)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5418"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "starting dose : 12.5 mg daily twice daily . ( 2.3 ) cautious titration divided schedule . ( 2.3 , 5.3 ) titration : increase total daily increments 25 mg 50 mg per day , well-tolerated . ( 2.3 ) target dose : 300 mg 450 mg per day , divided doses , end 2 weeks . ( 2.3 ) subsequent increases : increase increments 100 mg less , twice weekly . ( 2.3 ) maximum daily dose : 900 mg ( 2.3 ) tablets rapidly disintegrate placement mouth may chewed desired . water needed ( 2.3 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "12.5 mg yellow , round , flat-faced , beveled-edge , unscored tablet . debossed i3 one side plain side . available bottles 100 ( ndc 0093-5416-01 ) . 25 mg yellow , round , flat-faced , beveled-edge , unscored tablet . debossed i7 one side plain side . available bottles 100 ( ndc 0093-5417-01 ) cartons 48 tablets institutional ( 8x6 blister cards ) ( ndc 0093-5417-84 ) . 100 mg yellow , round , flat-faced , beveled-edge , unscored tablet . debossed i2 one side plain side . available bottles 100 ( ndc 0093-5419-01 ) cartons 48 tablets institutional ( 8x6 blister cards ) ( ndc 0093-5419-84 ) . 150 mg yellow , round , flat-faced , beveled-edge , unscored tablet . debossed i1 one side plain side . available bottles 100 ( ndc 0093-5376-01 ) cartons 48 tablets institutional ( 8x6 blister cards ) ( ndc 0093-5376-84 ) . 200 mg yellow , round , flat-faced , beveled-edge , unscored tablet . debossed l1 one side plain side . available bottles 100 ( ndc 0093-5377-01 ) cartons 48 tablets institutional ( 8x6 blister cards ) ( ndc 0093-5377-84 ) .",
    "adverseReactions": "clozapine orally disintegrating tablets contraindicated patients history serious hypersensitivity clozapine ( e.g . , photosensitivity , vasculitis , erythema multiforme , stevens-johnson syndrome ) component clozapine orally disintegrating tablets [ ( 6.2 ) ] .",
    "indications_original": "Clozapine orally disintegrating tablets are an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. ( 1.1 , 14.1 ) Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. ( 1.2 , 14.2 )",
    "contraindications_original": "Starting Dose: 12.5 mg once daily or twice daily. ( 2.3 ) Use cautious titration and divided dosage schedule. ( 2.3 , 5.3 ) Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated. ( 2.3 ) Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks. ( 2.3 ) Subsequent increases: increase in increments of 100 mg or less, once or twice weekly. ( 2.3 ) Maximum daily dose: 900 mg ( 2.3 ) Tablets rapidly disintegrate after placement in the mouth and may be chewed if desired. No water is needed ( 2.3 ).",
    "warningsAndPrecautions_original": "12.5 mg \n                        \n                        Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with I3 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5416-01).\n                           \n                           25 mg \n                        \n                        Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with I7 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5417-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5417-84). \n                        \n                           100 mg \n                        \n                        Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with I2 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5419-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5419-84).\n                        \n                           150 mg\n                        \n                        Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with I1 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5376-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5376-84).\n                        \n                           200 mg\n                        \n                        Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with L1 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5377-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5377-84).",
    "adverseReactions_original": "Clozapine orally disintegrating tablets are contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of clozapine orally disintegrating tablets\u00a0[see Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Clozapine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3766"
        }
    ]
}